Skip to product information
1 of 1

PE Mouse Anti-Human TIGIT Antibody (S-R730)

PE Mouse Anti-Human TIGIT Antibody (S-R730)

Catalog Number: S0B5868 Application: FCM Reactivity: Human Conjugation: PE Brand: Starter
Price:
Regular price $288.00 SGD
Regular price Sale price $288.00 SGD
Size:
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Mouse
Antigen TIGIT
Synonyms T-cell immunoreceptor with Ig and ITIM domains; V-set and immunoglobulin domain-containing protein 9; V-set and transmembrane domain-containing protein 3; VSIG9; VSTM3
Location Cell membrane
Accession Q495A1
Clone Number S-R730
Antibody Type Mouse mAb
Isotype IgG2a,k
Application FCM
Reactivity Hu
Positive Sample Human PBMC
Purification Protein A
Concentration 0.2 mg/ml
Conjugation PE
Physical Appearance Liquid
Storage Buffer

PBS, 1% BSA, 0.3% Proclin 300

Stability & Storage

12 months from date of receipt / reconstitution, 2 to 8 °C as supplied

Dilution


application dilution species
FCM 5μl per million cells in 100μl volume Hu

Background

TIGIT (T cell immunoglobulin and ITIM domain) is an inhibitory receptor expressed on lymphocytes, including natural killer (NK) cells and various subsets of T cells such as CD4+ T cells, CD8+ T cells, and regulatory T cells. It was discovered in 2009 through genome-wide analysis aiming to identify proteins containing domain structures typical for immunomodulatory receptors. TIGIT consists of one extracellular immunoglobulin variable domain, a type I transmembrane domain, and a short intracellular domain with one immunoreceptor tyrosine-based inhibitory motif (ITIM) and one immunoglobulin tyrosine tail (ITT)-like motif. Its main ligand is CD155, also known as poliovirus receptor (PVR), but it can also bind to CD112 and CD113 with lower affinity. TIGIT plays a significant role in down-regulating T cell and NK cell functions by interacting with these ligands expressed on antigen-presenting cells or tumor cells. This interaction inhibits immune cell responses at multiple steps of the cancer-immunity cycle, such as impairing T cell priming by dendritic cells, preventing tumor cell killing by NK cells and cytotoxic T cells, and enhancing the immune suppressive activity of regulatory T cells. Therefore, TIGIT has emerged as a major target in cancer immunotherapy. Several monoclonal antibodies that block the inhibitory activity of human TIGIT have been developed, and clinical trials are ongoing to investigate TIGIT blockade as a monotherapy or in combination with anti-PD1/PD-L1 antibodies for the treatment of patients with advanced solid malignancies.

Picture

FC

Flow cytometric analysis of Human TIGIT expression on Human PBMC. Human PBMC (peripheral blood mononuclear cells) were stained with Brilliant Violet 421™ Mouse Anti-Human CD4 Antibody and either PE Mouse IgG2a, κ Isotype Control (Left panel) or PE Mouse Anti-Human TIGIT Antibody (Right panel) at 5 μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.